Original report
The U.S. Food and Drug Administration approved Wegovy HD, a 7.2 mg once-weekly semaglutide injection, on March 19, 2026. FDA describes the approval as a higher dose for weight loss and long-term maintenance of weight loss in certain adult patients. Eligibility and use are governed by the current product labeling. The new strength is a regulatory update to an already established peptide medicine. It does not change the approved status of other substances sometimes discussed online, and it does not establish that higher doses are appropriate for any particular person.
What the FDA says
The FDA announcement identifies the medicine as semaglutide and notes approval of the higher dose. Patients should rely on the complete prescribing information for indications, contraindications, warnings and administration. Individual treatment decisions belong with a licensed healthcare professional.
Price and access
Manufacturer self-pay terms may differ by product strength, pharmacy channel, insurance status and savings-program eligibility. PeptideC records the offer date and links to the current manufacturer information. Prices can change, and insurance coverage is separate from a cash-pay price. FDA-approved semaglutide products are dispensed by prescription. FDA has cautioned that unapproved or compounded GLP-1 drugs are not FDA-reviewed for safety, effectiveness or quality before marketing, and can carry additional risks.
Sources & references
A chemical record identifies a reference, a study reports a defined investigation, and a product label concerns a specific medicine. A supplier catalogue is not clinical evidence.
General education, not personal medical advice. Ask an appropriately qualified professional about a medicine, symptom or treatment question.